The Experts below are selected from a list of 8040 Experts worldwide ranked by ideXlab platform

Robert A Delemos - One of the best experts on this subject based on the ideXlab platform.

Steven A Abrams - One of the best experts on this subject based on the ideXlab platform.

Frida Stock - One of the best experts on this subject based on the ideXlab platform.

  • phase i study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma
    Journal of Clinical Oncology, 2002
    Co-Authors: John F Toso, Vee J Gill, Patrick Hwu, Francesco M Marincola, Nicholas P Restifo, Douglas J Schwartzentruber, Richard M Sherry, Suzanne L Topalian, James Chihhsin Yang, Frida Stock
    Abstract:

    PURPOSE: A strain of Salmonella typhimurium (VNP20009), attenuated by chromosomal deletion of the purI and msbB genes, was found to target to tumor and inhibit tumor growth in mice. These findings led to the present phase I study of the intravenous infusion of VNP20009 to patients with metastatic cancer. PATIENTS AND METHODS: In cohorts consisting of three to six patients, 24 patients with metastatic melanoma and one patient with metastatic renal cell carcinoma received 30-minute intravenous bolus infusions containing 106 to 109 cfu/m2 of VNP20009. Patients were evaluated for dose-related toxicities, selective replication within tumors, and antitumor effects. RESULTS: The maximum-tolerated dose was 3 × 108 cfu/m2. Dose-limiting toxicity was observed in patients receiving 1 × 109 cfu/m2, which included thrombocytopenia, anemia, persistent bacteremia, hyperbilirubinemia, diarrhea, vomiting, nausea, Elevated Alkaline Phosphatase, and hypophosphatemia. VNP20009 induced a dose-related increase in the circulati...

  • phase i study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma
    Journal of Clinical Oncology, 2002
    Co-Authors: John F Toso, Vee J Gill, Francesco M Marincola, Nicholas P Restifo, Douglas J Schwartzentruber, Richard M Sherry, Suzanne L Topalian, James Chihhsin Yang, Frida Stock, Linda J Freezer
    Abstract:

    PURPOSE: A strain of Salmonella typhimurium (VNP20009), attenuated by chromosomal deletion of the purI and msbB genes, was found to target to tumor and inhibit tumor growth in mice. These findings led to the present phase I study of the intravenous infusion of VNP20009 to patients with metastatic cancer. PATIENTS AND METHODS: In cohorts consisting of three to six patients, 24 patients with metastatic melanoma and one patient with metastatic renal cell carcinoma received 30-minute intravenous bolus infusions containing 106 to 109 cfu/m2 of VNP20009. Patients were evaluated for dose-related toxicities, selective replication within tumors, and antitumor effects. RESULTS: The maximum-tolerated dose was 3 × 108 cfu/m2. Dose-limiting toxicity was observed in patients receiving 1 × 109 cfu/m2, which included thrombocytopenia, anemia, persistent bacteremia, hyperbilirubinemia, diarrhea, vomiting, nausea, Elevated Alkaline Phosphatase, and hypophosphatemia. VNP20009 induced a dose-related increase in the circulati...

John F Toso - One of the best experts on this subject based on the ideXlab platform.

  • phase i study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma
    Journal of Clinical Oncology, 2002
    Co-Authors: John F Toso, Vee J Gill, Patrick Hwu, Francesco M Marincola, Nicholas P Restifo, Douglas J Schwartzentruber, Richard M Sherry, Suzanne L Topalian, James Chihhsin Yang, Frida Stock
    Abstract:

    PURPOSE: A strain of Salmonella typhimurium (VNP20009), attenuated by chromosomal deletion of the purI and msbB genes, was found to target to tumor and inhibit tumor growth in mice. These findings led to the present phase I study of the intravenous infusion of VNP20009 to patients with metastatic cancer. PATIENTS AND METHODS: In cohorts consisting of three to six patients, 24 patients with metastatic melanoma and one patient with metastatic renal cell carcinoma received 30-minute intravenous bolus infusions containing 106 to 109 cfu/m2 of VNP20009. Patients were evaluated for dose-related toxicities, selective replication within tumors, and antitumor effects. RESULTS: The maximum-tolerated dose was 3 × 108 cfu/m2. Dose-limiting toxicity was observed in patients receiving 1 × 109 cfu/m2, which included thrombocytopenia, anemia, persistent bacteremia, hyperbilirubinemia, diarrhea, vomiting, nausea, Elevated Alkaline Phosphatase, and hypophosphatemia. VNP20009 induced a dose-related increase in the circulati...

  • phase i study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma
    Journal of Clinical Oncology, 2002
    Co-Authors: John F Toso, Vee J Gill, Francesco M Marincola, Nicholas P Restifo, Douglas J Schwartzentruber, Richard M Sherry, Suzanne L Topalian, James Chihhsin Yang, Frida Stock, Linda J Freezer
    Abstract:

    PURPOSE: A strain of Salmonella typhimurium (VNP20009), attenuated by chromosomal deletion of the purI and msbB genes, was found to target to tumor and inhibit tumor growth in mice. These findings led to the present phase I study of the intravenous infusion of VNP20009 to patients with metastatic cancer. PATIENTS AND METHODS: In cohorts consisting of three to six patients, 24 patients with metastatic melanoma and one patient with metastatic renal cell carcinoma received 30-minute intravenous bolus infusions containing 106 to 109 cfu/m2 of VNP20009. Patients were evaluated for dose-related toxicities, selective replication within tumors, and antitumor effects. RESULTS: The maximum-tolerated dose was 3 × 108 cfu/m2. Dose-limiting toxicity was observed in patients receiving 1 × 109 cfu/m2, which included thrombocytopenia, anemia, persistent bacteremia, hyperbilirubinemia, diarrhea, vomiting, nausea, Elevated Alkaline Phosphatase, and hypophosphatemia. VNP20009 induced a dose-related increase in the circulati...

Claire Mahaffey - One of the best experts on this subject based on the ideXlab platform.

  • Elevated Alkaline Phosphatase activity in a phosphate replete environment influence of sinking particles
    Limnology and Oceanography, 2017
    Co-Authors: Clare E Davis, Claire Mahaffey
    Abstract:

    Alkaline Phosphatase activity (APA) is traditionally a proxy for phosphate (DIP)-limitation because it is induced by DIP-limited microbes to access the labile ester fraction of the organic phosphorus (OP) pool. Here, we present multi-year summertime depth distributions of APA and enzyme kinetics in the DIP-replete Celtic Sea. Our findings support the cumulating body of evidence that APA has a potentially widespread role in OP remineralization through the water column. APA and Vmax were positively correlated with depth and DIP, with total APA being threefold higher below (0.93 ± 0.32 nM P h−1) compared to above the thermocline (0.30 ± 0.24 nM P h−1, p < 0.001). Separation of particles by sinking speed demonstrated that APA was eightfold higher on fast sinking (Ffast) particles compared to slow sinking particles (Fslow; p < 0.05). When normalized to particulate organic carbon (POC) and bacterial production (BP), APAPOC and APABP associated with Ffast (0.76 ± 0.10 nmol P μmol C−1 h−1, 21.13 ± 2.2 nmol P nmol C−1, respectively) were fourfold and 25-fold higher compared to the combined APA associated with dissolved plus suspended (Fsusp) and Fslow fractions (0.19 ± 0.06 nmol P μmol C−1 h−1 and 0.84 ± 0.23 nmol P nmol C−1, respectively). We postulate that this may reflect enhanced ectoenzyme activity associated with bacteria colonizing particle surfaces and/or release by zooplankton via faecal pellet excretion. Knowledge of the disparity between APA and BP associated with particle and dissolved phases is required to accurately define the O2 : P ratio of regenerated P derived from sinking particles as a result of AP-facilitated remineralization.